Inhibition of murine neutrophil recruitment in vivo by CXC chemokine receptor antagonists.
In this study, we have examined the ability of chemokine receptor antagonists to prevent neutrophil extravasation in the mouse. Two murine CXC chemokines, macrophage-inflammatory protein (MIP)-2 and KC, stimulated the accumulation of leukocytes into s.c. air pouches, although MIP-2 was considerably more potent. The leukocyte infiltrate was almost exclusively neutrophilic in nature. A human CXC chemokine antagonist, growth-related oncogene (GRO)-alpha(8-73), inhibited calcium mobilization induced by MIP-2, but not by platelet-activating factor in leukocytes isolated from the bone marrow, indicating that this antagonist inhibits MIP-2 activity toward murine leukocytes. Pretreatment of mice with GROalpha(8-73) inhibited, in a dose-dependent manner, the MIP-2-induced influx of neutrophils to levels that were not significantly different from control values. Moreover, this antagonist was also effective in inhibiting the leukocyte recruitment induced by TNF-alpha, LPS, and IL-1beta. Leukocyte infiltration into the peritoneal cavity in response to MIP-2 was also inhibited by prior treatment of mice with GROalpha(8-73) or the analogue of platelet factor 4, PF4(9-70). The results of this study indicate 1) that the murine receptor for MIP-2 and KC, muCXCR2, plays a major role in neutrophil recruitment to s.c. tissue and the peritoneal cavity in response to proinflammatory agents and 2) that CXCR2 receptor antagonists prevent acute inflammation in vivo.
McColl
S R
SR
Department of Microbiology and Immunology, University of Adelaide, Australia. smccoll@microb.adelaide.edu.au
Clark-Lewis
I
I
D000818:Animals; D002464:Cell Migration Inhibition; D002465:Cell Movement / Q000276:immunology*; D054360:Chemokine CXCL1; D054426:Chemokine CXCL2; D019743:Chemokines, CXC / Q000378:metabolism* / Q000494:pharmacology; D002630:Chemotactic Factors / Q000494:pharmacology; D015194:Diffusion Chambers, Culture; D006133:Growth Substances / Q000494:pharmacology; D007106:Immune Sera / Q000008:administration & dosage; D007116:Immunization, Passive; D007274:Injections, Intraperitoneal; D036341:Intercellular Signaling Peptides and Proteins; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D015846:Monokines / Q000276:immunology; D009504:Neutrophils / Q000276:immunology*; D010446:Peptide Fragments / Q000494:pharmacology; D010538:Peritonitis / Q000517:prevention & control; D010978:Platelet Factor 4 / Q000494:pharmacology; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*
C475829:CXCL1 protein, human; D054360:Chemokine CXCL1; D054426:Chemokine CXCL2; D019743:Chemokines, CXC; D002630:Chemotactic Factors; C475895:Cxcl1 protein, mouse; D006133:Growth Substances; D007106:Immune Sera; D036341:Intercellular Signaling Peptides and Proteins; D015846:Monokines; D010446:Peptide Fragments; D019707:Receptors, Chemokine; D010978:Platelet Factor 4